Relmada Therapeutics Inc (NAS:RLMD)
$ 0.3614 -0.0182 (-4.79%) Market Cap: 10.90 Mil Enterprise Value: -43.21 Mil PE Ratio: 0 PB Ratio: 0.23 GF Score: 33/100

Q2 2022 Relmada Therapeutics Inc Earnings Call Transcript

Aug 11, 2022 / 08:30PM GMT
Release Date Price: $27.82 (-4.99%)
Operator

Good day, ladies and gentlemen, and welcome to the Relmada Therapeutics, Inc. Second Quarter 2022 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Brian Ritchie of LifeSci Advisor. Please go ahead, sir.

Brian Ritchie
LifeSci Advisors, LLC - MD

Thank you, operator, and thank you all for joining us this afternoon. With me on today's call are Chief Executive Officer, Sergio Traversa; John Hixon, Head of Commercial; and Chief Financial Officer, Maged Shenouda. This afternoon, Relmada issued a news release providing a business update announcing financial results for the 3 and 6 months ended June 30, 2022, and filed its quarterly report on Form 10-Q with the SEC.

Please note that certain information discussed on the call today is covered under the safe harbor provision of the Private Securities Litigation Reform Act. We caution listeners that during this call, while Relmada's management team will be making forward-looking statements. Actual results could differ materially from those

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot